Investors / Canada / CTI Life Sciences Fund
CTI Life Sciences Fund
Venture capital · Canada · North America
CTI Life Sciences Fund is a biotech venture capital firm that invests in and builds early-stage therapeutic companies. It describes itself as a company builder that turns nascent ideas and assets into investable biotech companies.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticslife sciencescompany buildingsirnaimmuno-oncology
Your fit with CTI Life Sciences Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCTI Life Sciences Fund lists 13 checked portfolio companies on its own site and is named in 5 funding rounds, 2 of them as lead. Its most frequent entry is Series B, 60% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in United States. It invests most often alongside Foresite Capital, Lumira Ventures and adMare BioInnovations.
Counts come from funding rounds that name CTI Life Sciences Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not CTI Life Sciences Fund's whole history. Rounds on record name 5 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundCTI Life Sciences Fund does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 20% |
| Series B | 60% |
| Growth | 20% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 3 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 98th | 38% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Foresite Capital | 3 |
| Lumira Ventures | 3 |
| adMare BioInnovations | 3 |
| Advent Life Sciences | 2 |
| Omega Funds | 2 |
| Viva BioInnovator | 2 |
| 3B Future Health Fund | 1 |
| AV8 Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Foresite Capital
Compare CTI Life Sciences Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with CTI Life Sciences Fund| Date | Company | Stage |
|---|---|---|
| 3 Nov 2026 | Series B | |
| 10 Feb 2026 | Series B | |
| 9 Jan 2026 | Series A Led | |
| 16 Dec 2025 | Series B | |
| 16 Apr 2025 | Series C+ Led |
Round details for CTI Life Sciences Fund
Amounts, full round histories and every co-investor in CTI Life Sciences Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. | Healthcare & Biotech | Portfolio page | ||
| Aeovian Pharmaceuticals develops small molecules to treat certain rare genetic and age-related diseases | Healthcare & Biotech | Dec 2025Series B | Page + round | |
| Domain Therapeutics develops breakthrough GPCR-targeting therapies for patients, especially in immuno-oncology and inflammation. | Healthcare & Biotech | Feb 2026Series B | Page + round | |
| enGene develops non-viral therapeutics for urological cancers, starting with non-muscle invasive bladder cancer | Healthcare & Biotech | Portfolio page | ||
| Epitopea develops cancer RNA immunotherapies | Healthcare & Biotech | Portfolio page | ||
| The company designs ground-breaking therapies through precision-targeting of membrane receptors to treat demyelinating diseases | Healthcare & Biotech | Jan 2026Series A | Page + round | |
| Glycomine is developing replacement therapies for rare genetic diseases | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| Phenomic AI develops therapeutic approaches for solid tumors using single-cell data and machine learning | Healthcare & Biotech | Portfolio page | ||
| Profound Medical develops and provides incision-free therapies, including transurethral ultrasound ablation of the prostate tissue | Healthcare & Biotech | Portfolio page | ||
| Thryv Therapeutics is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision medicines for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. | Healthcare & Biotech | Nov 2026Series B | Page + round | |
| Vaxcyte is dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep and Shigella through vaccine innovation | Healthcare & Biotech | Portfolio page | ||
| Visterra is a biologics research company developing therapies for patients with immune-mediated and other hard-to-treat diseases. | Healthcare & Biotech | Portfolio page | ||
| Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing novel, multifunctional biotherapeutics for difficult-to-treat diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- ctisciences.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Apr 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get CTI Life Sciences Fund's profile as data
Pull CTI Life Sciences Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/ctisciences.com
# also
GET /v1/firms/ctisciences.com/portfolio
GET /v1/firms/ctisciences.com/coinvestors
GET /v1/firms/ctisciences.com/news